Prenetics Global Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Prenetics Global wird ein Gewinn- und Umsatzwachstum von 76.9% bzw. 93.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 84.5% pro Jahr wachsen soll.

Wichtige Informationen

76.9%

Wachstumsrate der Gewinne

84.5%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.9%
Wachstumsrate der Einnahmen	93.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Prenetics Global Limited's (NASDAQ:PRE) Earnings Haven't Escaped The Attention Of Investors

Oct 12

Prenetics Global Limited (NASDAQ:PRE) Looks Just Right With A 29% Price Jump

May 29

Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues

Apr 08

Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%

Jan 07

Prenetics Global GAAP EPS of -$2.91, revenue of $51.72M

Sep 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:PRE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	90	-9	N/A	N/A	1
12/31/2024	35	-43	N/A	N/A	1
6/30/2024	23	-43	N/A	N/A	N/A
3/31/2024	23	-50	N/A	N/A	N/A
12/31/2023	22	-54	-15	-14	N/A
9/30/2023	280	-18	N/A	N/A	N/A
6/30/2023	279	-23	N/A	N/A	N/A
3/31/2023	201	-168	N/A	N/A	N/A
12/31/2022	13	-226	8	15	N/A
9/30/2022	288	-278	N/A	N/A	N/A
6/30/2022	283	-343	-27	-19	N/A
3/31/2022	310	-209	N/A	N/A	N/A
12/31/2021	13	-219	2	13	N/A
9/30/2021	238	-94	3	15	N/A
6/30/2021	190	-4	-15	-6	N/A
3/31/2021	119	1	-14	-8	N/A
12/31/2020	65	-2	-6	-3	N/A
12/31/2019	9	-20	-2	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PRE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PRE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PRE wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PREDie Einnahmen des Unternehmens (93.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: PREDie Einnahmen des Unternehmens (93.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PRE in 3 Jahren voraussichtlich hoch sein wird

Prenetics Global Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Prenetics Global Limited Reaffirms Revenue Guidance for the Year 2024

Consensus revenue estimates fall by 30%

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 17%

Consensus revenue estimates fall by 23%

Consensus revenue estimates decrease by 12%

Recent updates

Prenetics Announces the Launch of IM8 Health

Prenetics Global Limited's (NASDAQ:PRE) Earnings Haven't Escaped The Attention Of Investors

Prenetics Global Limited (NasdaqGM:PRE) acquired Europa Sports Partners, LLC.

Prenetics Global Limited Reaffirms Revenue Guidance for the Year 2024

Prenetics Global Limited (NASDAQ:PRE) Looks Just Right With A 29% Price Jump

New major risk - Share price stability

Prenetics Global Limited's (NASDAQ:PRE) 36% Cheaper Price Remains In Tune With Revenues

New minor risk - Profitability

Full year 2023 earnings released: US$4.83 loss per share (vs US$37.57 loss in FY 2022)

New minor risk - Share price stability

Prenetics Global Limited Announces Board Appointments

Prenetics Global Limited (NASDAQ:PRE) Held Back By Insufficient Growth Even After Shares Climb 30%

Consensus revenue estimates fall by 30%

Forecast breakeven date pushed back to 2025

Consensus revenue estimates decrease by 17%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

New major risk - Shareholder dilution

Consensus revenue estimates fall by 23%

Prenetics Global Limited Appoints Joel Neoh as Chief Consumer Officer

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 12%

Forecast breakeven date moved forward to 2024

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2025

Prenetics Global Limited Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

Prenetics Global Limited (NasdaqGM:PRE) agreed to acquire unknown majority stake in ACT Genomics Co., Ltd. from Sanomics Holdings Limited for $58.4 million.

Prenetics Global Limited (NasdaqGM:PRE) announces an Equity Buyback for $20 million worth of its shares.

Less than half of directors are independent

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Prenetics Global Limited Revises Earnings Guidance for the Full Year 2022

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Prenetics Global Limited Provides Revenue Guidance for Third Quarter of 2022

Prenetics Global GAAP EPS of -$2.91, revenue of $51.72M

Prenetics Global Limited Launches Circle Snapshot, Simple At-Home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device

Prenetics Group Limited Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong

First quarter 2022 earnings: EPS misses analyst expectations

Prenetics Group Limited completed the acquisition of Artisan Acquisition Corp. (NasdaqCM: ARTA) from Artisan LLC and others.

Prenetics Group Limited completed the acquisition of Artisan Acquisition Corp. (NasdaqCM: ARTA) from Artisan LLC and others.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken